Currently out of the existing stock ratings of Etzer Darout, 91 are a BUY (71.65%), 36 are a HOLD (28.35%).

Etzer Darout

Work Performance Price Targets & Ratings Chart

Analyst Etzer Darout, currently employed at GUGGENHEIM, carries an average stock price target met ratio of 49.32% that have a potential upside of 42.76% achieved within 120 days.

Etzer Darout’s has documented 252 price targets and ratings displayed on 28 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on SRRK, Scholar Rock Holding Corp at 07-Aug-2025.

Wall Street Analyst Etzer Darout

Analyst best performing recommendations are on FPRX (FIVE PRIME THERAPEUTICS).
The best stock recommendation documented was for MGNX (MACROGENICS) at 7/11/2022. The price target of $4 was fulfilled within 2 days with a profit of $0.45 (12.68%) receiving and performance score of 63.38.

Average potential price target upside

of $31.46 (22.45%) on SGEN (SEAGEN).
of $26.39 (27.86%) on BNTX (BIONTECH SE).
of $20.77 (89.94%) on MRUS (MERUS BV).

DMAC DiaMedica Therapeutics MGNX MacroGenics MIRM Mirum Pharmaceuticals VERV Verve Therapeutics CTMX CytomX Therapeutics EXEL Exelixis FATE Fate Therapeutics GMAB Genmab AS IMGN ImmunoGen MRUS Merus BV SGEN Seagen NUVL Nuvalent XNCR Xencor FPRX Five Prime Therapeutics ALNY Alnylam Pharmaceuticals YMAB Y mAbs Therapeutics ARVN Arvinas FTSV Forty Seven AZN AstraZeneca PLC ADR CCCC C4 Therapeutics IVA Inventiva Sa BNTX BioNTech SE IGMS IGM Biosciences NVS Novartis AG ADR SRRK Scholar Rock Holding Corp TERN Terns Pharmaceuticals ACRV Acrivon Therapeutics, Common Stock QTTB Q32 Bio

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Matthew Caufield (HC WAINWRIGHT)